Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial

Schizophrenia-spectrum disorders (SSD) are associated with increased inflammatory markers, both in brain and periphery. Augmentation with drugs that lower this pro-inflammatory status may improve clinical presentation. Simvastatin crosses the blood-brain barrier, has anti- inflammatory and neuroprot...

Full description

Saved in:
Bibliographic Details
Published in:Schizophr Bull
Main Authors: Sommer, Iris E, Gangadin, Shiral S, de Witte, Lot D, Koops, Sanne, van Baal, C, Bahn, Sabine, Drexhage, Hemmo, van Haren, N E M, Veling, Wim, Bruggeman, R, Martens, Peter, Wiersma, Sybren, Veerman, Selene R T, Grootens, Koen P, van Beveren, Nico, Kahn, Rene S, Begemann, Marieke J H
Format: Artigo
Language:Inglês
Published: Oxford University Press 2021
Subjects:
Regular Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8266622/
https://ncbi.nlm.nih.gov/pubmed/33608711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbab010
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items